Приказ основних података о документу

dc.creatorBožić, Bojana
dc.creatorVidonja Uzelac, Teodora
dc.creatorKezić, Aleksandra
dc.creatorBajčetić, Milica
dc.date.accessioned2018-05-17T09:14:02Z
dc.date.available2018-05-17T09:14:02Z
dc.date.issued2018
dc.identifier.urihttp://www.eurekaselect.com/153927/article
dc.identifier.urihttp://ibiss-r.rcub.bg.ac.rs/123456789/3052
dc.description.abstractHistorically, quinidine was the first medicine used in the therapy of heart arrhythmias. Studies in the early 20th century identified quinidine, a diastereomer of the antimalarial quinine, as the most potent of the antiarrhythmic substances extracted from the cinchona plant. Quinidine is used by the 1920s, as an antiarrhythmic agent to maintain sinus rhythm after the conversion from atrial flutter or atrial fibrillation and to prevent recurrence of ventricular tachycardia or ventricular fibrillation. Its value in chronic prophylaxis of relapse of ventricular arrhythmia was brought under suspicion after publishing of meta analysis that showed that the application of quinidine increases mortality. Due to numerous proofs of increased risk for the appearance of ventricular arrhythmia and sudden death, as well as a number of other adverse effects and drug interactions, quinidine was withdrawn from use and in the recent years has become unavailable in many countries. On the other hand, recent studies have demonstrated that quinidine is the only oral medication that has consistently shown efficacy in preventing arrhythmias and terminating storms due to recurrent ventricular fibrillation, in patients with Brugada syndrome, idiopathic ventricular fibrillation and early repolarization syndrome. Quinidine is also the only antiarrhythmic drug that normalized the QT interval in patients with the congenital short QT syndrome. The aim of this review is to provide good insight into pro and contra arguments for quinidine use in ventricular arrhythmias evidence based on recently published literature.
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173014/RS//
dc.rightsclosedAccess
dc.sourceMini Reviews in Medicinal Chemistry
dc.subjectAlkaloid
dc.subjectBrugada
dc.subjectHeart
dc.subjectQuinidine
dc.subjectRepolarization
dc.subjectUse
dc.subjectVentricular arrhythmias
dc.subject.otherm22
dc.titleThe Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.
dc.typearticleen
dc.rights.licenseARR
dcterms.abstractВидоња Узелац, Теодора; Бајчетић, Милица; Кезић, Aлександра; Божић, Бојана;
dc.rights.holder© 2018 Bentham Science Publishers.
dc.citation.issue6
dc.citation.volume18
dc.identifier.doi10.2174/1389557517666170707110450
dc.identifier.pmid28685701
dc.identifier.scopus2-s2.0-85045893196
dc.identifier.wos000427821200002
dc.citation.apaBozic, B., Uzelac, T. V., Kezic, A., & Bajcetic, M. (2018). The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias “Quinidine”. Mini Reviews in Medicinal Chemistry, 18(6), 468–475.
dc.citation.vancouverBozic B, Uzelac TV, Kezic A, Bajcetic M. The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias “Quinidine”. Mini Rev Med Chem. 2018;18(6):468–75.
dc.citation.spage468
dc.citation.epage475


Документи

ДатотекеВеличинаФорматПреглед

Нема фајлова за овај рад.

Овај рад се појављује у следећим колекцијама

Приказ основних података о документу